| Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma A Jayachandran, M Anaka, P Prithviraj, C Hudson, SJ McKeown, PH Lo, ... Oncotarget 5 (14), 5782, 2014 | 138 | 2014 |
| Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy S Bowyer, P Prithviraj, P Lorigan, J Larkin, G McArthur, V Atkinson, ... British Journal of Cancer 114 (10), 1084-1089, 2016 | 133 | 2016 |
| Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma R Shrestha, P Prithviraj, M Anaka, KR Bridle, DHG Crawford, B Dhungel, ... Frontiers in oncology 8, 269, 2018 | 131 | 2018 |
| Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma R Sharma, E Kadife, M Myers, G Kannourakis, P Prithviraj, N Ahmed Journal of Experimental & Clinical Cancer Research 40 (1), 186, 2021 | 89 | 2021 |
| Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma V Atkinson, A Khattak, A Haydon, M Eastgate, A Roy, P Prithviraj, ... Journal for immunotherapy of cancer 8 (2), 2020 | 72 | 2020 |
| Identifying and targeting determinants of melanoma cellular invasion A Jayachandran, P Prithviraj, PH Lo, M Walkiewicz, M Anaka, BL Woods, ... Oncotarget 7 (27), 41186, 2016 | 53 | 2016 |
| Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion P Prithviraj, M Anaka, SJ McKeown, M Permezel, M Walkiewicz, J Cebon, ... Oncotarget 6 (18), 15953, 2015 | 43 | 2015 |
| Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells A Jayachandran, PH Lo, AC Chueh, P Prithviraj, R Molania, ... BMC cancer 16, 1-15, 2016 | 42 | 2016 |
| Combined inhibition of TGF-β1-induced EMT and PD-L1 silencing re-sensitizes hepatocellular carcinoma to sorafenib treatment R Shrestha, P Prithviraj, KR Bridle, DHG Crawford, A Jayachandran Journal of Clinical Medicine 10 (9), 1889, 2021 | 26 | 2021 |
| Prognostic role of immune checkpoint regulators in cholangiocarcinoma: a pilot study L Cao, P Prithviraj, R Shrestha, R Sharma, M Anaka, KR Bridle, ... Journal of clinical medicine 10 (10), 2191, 2021 | 12 | 2021 |
| Embryonic chicken transplantation is a promising model for studying the invasive behavior of melanoma cells A Jayachandran, SJ McKeown, BL Woods, P Prithviraj, J Cebon Frontiers in Oncology 5, 36, 2015 | 10 | 2015 |
| Crosstalk between immune checkpoint modulators, metabolic reprogramming and cellular plasticity in triple-negative breast cancer A Poddar, SR Rao, P Prithviraj, G Kannourakis, A Jayachandran Current Oncology 29 (10), 6847-6863, 2022 | 8 | 2022 |
| CD73 and PD-L1 as potential therapeutic targets in gallbladder cancer L Cao, KR Bridle, R Shrestha, P Prithviraj, DHG Crawford, ... International Journal of Molecular Sciences 23 (3), 1565, 2022 | 8 | 2022 |
| Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes P Prithviraj, M Anaka, EW Thompson, R Sharma, M Walkiewicz, ... Scientific reports 10 (1), 13779, 2020 | 7 | 2020 |
| Precision medicine: an optimal approach to patient care in renal cell carcinoma R Sharma, G Kannourakis, P Prithviraj, N Ahmed Frontiers in Medicine 9, 766869, 2022 | 6 | 2022 |
| Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. P Prithviraj, GA McArthur, V Atkinson, P Parente, MC Andrews, S Parakh, ... Journal of Clinical Oncology 33 (15_suppl), 9059-9059, 2015 | 5 | 2015 |
| UNISON-nivolumab then ipilimumab+ nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy C Gedye, DW Pook, LEM Krieger, CA Harris, JC Goh, G Kichenadasse, ... J. Clin. Oncol 39 (325), 10.1200, 2021 | 3 | 2021 |
| In vitro and in silico analysis of epithelial-mesenchymal transition and cancer stemness as prognostic markers of clear cell renal cell carcinoma R Sharma, S Balta, A Raza, RM Escalona, G Kannourakis, P Prithviraj, ... Cancers 15 (9), 2586, 2023 | 2 | 2023 |
| Ipilimumab+ nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab+ nivolumab in … C Gedye, DW Pook, LEM Krieger, C Harris, JC Goh, G Kichenadasse, ... J Clin Oncol 39 (suppl 15), 4565, 2021 | 2 | 2021 |
| Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib R Sharma, E Kadife, G Kannourakis, N Ahmed, P Prithviraj Annals of Oncology 30, ix73, 2019 | 2 | 2019 |
Andreas BehrenOlivia Newton-John Cancer Research InstituteVerified email at onjcri.org.au
